Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients (Keppra-2)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Out-patients with alcohol dependence recently detoxified Primary goal size is the duration of the Abstinenz up to the heavy relapse.
Secondary objective size are:
- Frequency of Lapses
- Time up to the first alcohol drinking
- cumulative times of do not drink
- Craving
- Alcohol drinking quantity
- Sleep quality
- Tolerability/Bearableness of the study medication
- Security
- Drop Out rate
- Side effects
- Changes with the neuropsychological testing HAM-A, HAM-D, SF12, PSQI, VASC, OCDS, TLFB, SCL-90.
- Quality of life
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie
-
Berlin, Germany, 10559
- PUK Charité im SHK
-
Berlin, Germany, 12099
- Vivantes, Wenckebach-Krankenhaus, Klinik für Psychiatrie und Psychotherapie, Gerontopsychiatrie/Psychosomatik
-
Berlin, Germany, 13347
- Klinik für Psychiatrie und Psychotherapie, Jüdisches Krankenhaus Berlin
-
-
Bayern
-
Nürnberg, Bayern, Germany, 90419
- Klinikum Nürnberg Nord
-
-
NRW
-
Bochum, NRW, Germany, 44791
- Westfälisches Zentrum Bochum, Psychiatrie, Psychotherapie & Psychosomatik, Klinik der Ruhr-Universität
-
Bonn, NRW, Germany, 53105
- Klinik und Poliklinik für Psychiatrie und Psychotherapie
-
Essen, NRW, Germany, 45136
- Klinik für Psychiatrie, Psychotherapie und Suchtmedizin Kliniken Essen - Mitte
-
Essen, NRW, Germany, 45147
- Klinik für abhängiges Verhalten und Suchtmedizin, Rheinische Kliniken Essen, Kliniken der Universität Duisburg-Essen
-
Essen, NRW, Germany, 45147
- Klinik für abhängiges Verhalten und Suchtmedizin, Rheinische Kliniken, Essen, Kliniken der Universität Duisburg - Essen
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06097
- Klinik für Psychiatrie und Psychotherapie der Martin-Luther-Universität Halle
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 and not older than 70 years
- Good knowledge of the German language
- The criteria of an alcohol dependence after DSM IV and ICD 10 fulfill
- To the recruiting time alkoholabstinently living, i.e. after successful alcohol decontamination, the patients must have understood the meaning and consequence of the study and have delivered before beginning of study your written agreement to the participation.
- Negative drug screening regarding Benzodiazepines and Opiates.
- With Females either o at least 1 year Menopause or after Sterilization or contraceptive pill, mini pill, three-monthly syringe, Implanton, Vaginalring, hormone plaster, hormone spiral at least 1 month before study inclusion or use of the double barrier method with Spermiziddiaphragma plus condom use or renouncement of sexual intercourse during the entire study duration and resolution a pregnancy to avoid with negative β-HCG-test
Exclusion Criteria:
- Alcohol withdrawal syndrome beginning or existing
- Simultaneous one ambulatory or stationary curing therapy, not however participation in groups of self-helps
- Specific ones behavior or deep-psychological single therapy or manual-led group therapies parallel to the clinical study
- Any further substance dependence except nicotine and/or Caffeine dependence A abuse according to the criteria of DSM-IV and/or ICD-10 is not considered as exclusion reason.
- Idiopathic epilepsy, not however admitted alcohol withdrawal convulsions
- Anamnesis of heavy cerebral traumas or other heavy neurological illnesses, not however alcohol-associated neurological disturbances, e.g. Polyneuropathie
- current CO-medication by means of medicines, which can affect significantly withdrawal symptoms or Craving or promote the Abstinent( Benzodiazepines, Antiepileptics, antipsychotics, Clonidin, antidepressives or Naltrexon (or substances with comparable effect mechanism) or Acamprosat, Disulfiram, or further substances, which can affect glutamaterge, dopaminerge, cholinergic, serotonerge or opiode system the GABAerge,
- Contraindications or heavy side effects in relation to the study medication, hypersensitivity opposite Pyrrolidonderivate
- Pregnancy or quiet time or insufficient Contraception
- Acute severe psychiatric disturbances in need of treatment of the axle I after DSM-IV
- Acute Suizidalität, not convincingly arrangementable
- Severe internal illnesses, e.g. Pancreatitis, pneumonia, cardiac infarct, gastrointestinal bleedings etc.)
- Severe kidney damage (starting from dekompensierter retention - stage 3 after that national Kidney Foundation) or heavy liver damage (starting from Child A after Child Pugh Score with living ore erring trousers) and/or creatinin Clearance of small 30ml/min
- Simultaneous participation or within the last 4 weeks at another clinical study, however does not exist an exclusion with previous participation in the decontamination study with Keppra ® (Keppra 1).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Sugar Pill
|
|
Active Comparator: Levetiracetam
|
levetiracetam daily application 1500-2000 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison alcohol free "surviving "(heavy alcohol relapse) between experimental therapy (Keppra®) and a group of placebos
Time Frame: During and after treatment
|
During and after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
1 Time up to first drinking
Time Frame: During treatment
|
During treatment
|
|
2 cumulative Time of do not drinking over the study duration
Time Frame: during treatment
|
during treatment
|
|
3 Frequency of Lapses
Time Frame: during treatment
|
during treatment
|
|
Tolerability of the study medication
Time Frame: during treatment
|
during treatment
|
|
Drop Out rate
Time Frame: during treatment
|
during treatment
|
|
Side effects
Time Frame: during treatment
|
during treatment
|
|
Changes with the neuropsychological testing, HAM-A, HAM-D, SF12, VASC, OCDS, TLFB, SCL-90
Time Frame: during treatment
|
during treatment
|
|
Quality of life
Time Frame: during treatment
|
during treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Martin Schaefer, MD, Department of Psychiarty, Charite Campus Mitte, Berlin, and Department of Psychiatry, Kliniken Essen-Mitte, Essen, Germany
Publications and helpful links
General Publications
- Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol. 2006 Jun;26(3):347-9. doi: 10.1097/01.jcp.0000219926.49799.89. No abstract available.
- Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, Heinz A, Forg A, Volkmar K, Glauner T, Schaefer M. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol. 2012 Aug;32(4):558-62. doi: 10.1097/JCP.0b013e31825e213e.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Kep-F10.2.01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.